Survodutide Research Hub — GLP-1 / Glucagon Dual Agonist Studies
Survodutide (BI 456906) is a dual agonist at the GLP-1 and glucagon receptors investigated in metabolic, hepatic-steatosis and energy-balance research models.
What this hub covers
- Dual GLP-1 / glucagon receptor agonism
- Hepatic-steatosis (MASLD) research literature
- Energy expenditure and body-composition endpoints
- Comparisons to tirzepatide and retatrutide
- Reconstitution and storage
Survodutide research articles
All research →Survodutide Benefits and Side Effects: A Research Guide
Research guide on Survodutide (BI 456906): dual GLP-1 / glucagon receptor agonism, MASLD and metabolic literature, and the documented side-effect profile.
Read article →Tirzepatide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and semaglutide/Retatrutide comparisons for tirzepatide — the GLP-1/GIP dual agonist that established GIP-receptor co-agonism as a productive metabolic axis.
Read article →Retatrutide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and tirzepatide/semaglutide comparisons for Retatrutide — the investigational GLP-1/GIP/glucagon triple agonist with the largest body-weight reductions reported for any non-surgical incretin pharmacotherapy.
Read article →Survodutide Dosing & Protocols — Research Reference
Reference dose tiers, titration ladder, reconstitution math, and weekly-injection scheduling from the published survodutide (GLP-1/glucagon dual agonist) research record.
Read article →Survodutide research FAQ
- What is Survodutide?
- Survodutide is an investigational GLP-1 / glucagon dual receptor agonist studied in metabolic and hepatic-steatosis research models.
- How is it different from semaglutide?
- Semaglutide is a GLP-1 mono-agonist; Survodutide adds glucagon-receptor agonism for an energy-expenditure component described in the published literature.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.